▲ bullish
Impact
PhaseFiled / BLA under FDA review
Time to marketFDA decision expected Q1 2027; US launch could follow in H1 2027 if approved.
AVT16 vedolizumab Updated Aug 1
What to watch
Watch for (1) any FDA review updates on AVT16 ahead of the expected Q1 2027 decision; (2) the earlier AVT05/AVT06 FDA decisions (late 2026) as a read-through on manufacturing compliance; (3) Fresenius PB016's review timeline, which determines how long Alvotech's first-mover window stays open; (4) further financing/dilution given the ~$107.6M Q1 2026 cash burn and high-cost debt.
Bull case
- First vedolizumab (Entyvio) biosimilar BLA accepted for FDA review (June 8, 2026), with interchangeability requested, potential first-to-market head start vs competitors.
- Enormous reference market: Entyvio was Takeda's top-selling product at JPY 914.1B (~$6B) in FY ended March 2025; Q1 FY2025 sales were $1.54B.
- If approved, AVT16 will be marketed by Teva in the US under an existing partnership, Teva has a large US GI commercial footprint.
Bear case
- Direct competition already in the FDA queue: Fresenius Kabi/Polpharma PB016 BLA accepted July 31, 2026, only ~2 months behind, narrowing the first-mover window; PB016 also received EMA acceptance.
- Approval is not guaranteed; Alvotech has a history of Complete Response Letters (CRLs) tied to manufacturing deficiencies at the Reykjavik facility.
- Decision is ~6-8 months away (Q1 2027), and AVT16 is one of three pending BLAs; AVT05 and AVT06 decisions are expected in late 2026 and could preoccupy investors.